• All Categories
  • Infectious Diseases
  • Rare Diseases
  • Dermatology
  • Oncology
  • Respiratory
  • Pain
  • Neurology
  • Cardiovascular
  • Women's Health
  • News
Contents
Contents

This issue includes the latest news, as well as articles on Cardiovascular and Metabolic Diseases, Women's Health, and Oncology.

1 October 2023
INTCR
INTCR

Www.pharmatimes.com/intcr

1 October 2023
Comment
Comment

Welcome to the autumn 2023 issue of Pharmafile! As the summer draws to a close, it is an ideal time to consider 2023 so far and where it might take us in the remaining months.

1 October 2023
Pharmafile autumn 2023
Pharmafile autumn 2023

Welcome to the Autumn 2023 issue of Pharmafile!

1 October 2023
Pharmafile
Pharmafile

Www.pharmafile.com

1 October 2023
Pfizer’s RSV vaccine recommended by CDC
Pfizer’s RSV vaccine recommended by CDC

Pfizer has announced that the CDC Advisory Committee on Immunization Practices (ACIP) has recommended the company’s bivalent respiratory syncytial virus (RSV) vaccine, Abrysvo, for maternal immunisation.

1 October 2023News
Eli Lilly & Boehringer Ingelheim’s Jardiance approved by FDA for treatment of chronic kidney disease
Eli Lilly & Boehringer Ingelheim’s Jardiance approved by FDA for treatment of chronic kidney disease

Eli Lilly and Boehringer Ingelheim have announced that the FDA has approved Jardiance (empagliflozin) 10mg tablets to reduce risk of sustained decline in estimated glomerular filtration rate (EGFR), end-stage kidney disease, cardiovascular death and hospitalisation in adults with chronic kidney disease (CKD).

1 October 2023News
FDA approves GSK’s Ojjaara for the treatment of patients with myelofibrosis and anaemia
FDA approves GSK’s Ojjaara for the treatment of patients with myelofibrosis and anaemia

GSK has announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofibrosis in adults with anaemia.

1 October 2023News
Menarini Group’s Orserdu approved by European Commission for breast cancer
Menarini Group’s Orserdu approved by European Commission for breast cancer

The Menarini Group and its subsidiary Stemline Therapeutics have announced that the European Commission (EC) has approved Orserdu (elacestrant) as a monotherapy for the treatment of post-menopausal women and men with oestrogen receptor (er)-positive, her2-negative, locally advanced or metastatic breast cancer (mbc) with an activating esr1 mutation who have experienced disease progression following at least one prior endocrine therapy.

1 October 2023News
AstraZeneca and Daiichi Sankyo share positive results from phase 3 trial of datopotamab der uxtecan
AstraZeneca and Daiichi Sankyo share positive results from phase 3 trial of datopotamab der uxtecan

AstraZeneca and Daiichi Sankyo have shared positive high-level results from the tropion-breast01 phase 3 trial, which showed datopotamab deruxtecan demonstrating a statistically significant and clinically meaningful improvement in progression-free survival compared to chemotherapy in patients with inoperable or metastatic hormone receptor (hr)-positive, her2-low or negative breast cancer.

1 October 2023News
CEPI and BioNTech partner for development of mRNA mpox vaccine
CEPI and BioNTech partner for development of mRNA mpox vaccine

BioNTech and the Coalition for Epidemic Preparedness Innovations (CEPI) have announced a partnership to advance the development of mRNA-based vaccine candidates for the prevention of mpox.

1 October 2023News
Bristol Myers Squibb hosts R&D day, shares new research and development plans
Bristol Myers Squibb hosts R&D day, shares new research and development plans

Bristol Myers Squibb (BMS) recently held a research and development day in New York, US, in order to discuss the company’s R&D strategy and capabilities while providing insights into its pipeline and long-term growth plans.

1 October 2023News